Click here for more information about how we are dealing with COVID-19 and what you should do for your visit.
Skip to main content

FDA Approves Leqembi, Expanding Alzheimer's Treatment, with Contributions from Neurology Diagnostics

We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s. 

This approval is a significant achievement, particularly for our clinic, Neurology Diagnostics has extensive experience working with anti-amyloid therapies, having enrolled patients in clinical trials here in Dayton, OH since 2018.  We look forward to continuing to guide our patients in determining the best options in the assessment and treatment of memory disorders. 

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide. Finding effective treatments for this challenging condition has long been a goal for medical professionals and researchers. The recent FDA approval of Leqembi marks a major step forward. Developed by NeuroPharma, Leqembi belongs to a category known as anti-amyloid beta monoclonal antibodies.

Leqembi works by targeting the buildup of amyloid beta plaques in the brain, which are a key characteristic of Alzheimer's disease. These plaques disrupt normal brain function, leading to cognitive decline and memory loss. By binding to these plaques, Leqembi helps remove them from the brain, potentially slowing down disease progression and improving cognitive function in individuals with Alzheimer's.

At Neurology Diagnostics Research, we have actively engaged in the research and development of drugs in the same class as Leqembi since 2018. Our dedicated team has conducted clinical trials, collaborated with pharmaceutical companies, and closely worked with patients and their families to contribute to the development of new therapeutic options.

One of the most significant outcomes of the FDA's approval of Leqembi is the expansion of treatment options for a broader range of patients. Previously, Alzheimer's drugs were primarily prescribed during the early stages of the disease. However, Leqembi's approval allows for treatment in individuals with mild Alzheimer's, providing hope to a larger population affected by this devastating condition.

Clinical studies play a vital role in advancing medical breakthroughs, and our involvement in researching drugs similar to Leqembi has been instrumental in developing effective treatment options. Through rigorous testing and evaluation, we have contributed to the scientific understanding of the safety, effectiveness, and potential side effects of these drugs. The participation of our patients in these studies has been invaluable in bringing us closer to improved treatments for Alzheimer's disease.

The FDA's approval of Leqembi represents a momentous development in the treatment of Alzheimer's disease. At Neurology Diagnostics, we are proud to have been involved in the research and development of drugs similar to Leqembi. This milestone offers hope to countless individuals affected by Alzheimer's and their loved ones. With continued research, collaboration, and unwavering dedication, we remain optimistic about the future of Alzheimer's treatment and the eventual discovery of a cure.

Sarah Blackman Marketing Manager

You Might Also Enjoy...

Brain imaging showing loss in serotonin function as Parkinson's disease progresses. Red/yellow areas show that serotonin func

Parkinson's Disease Clinical Trial

Parkinson's disease afflicts over one million people in the United States causing a decline in motor skills and cognition due to the destruction of dopamine producing neurons in the brain. Current research targets dopamine receptors in the brain.